Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 and up

Botulinum toxin A injection before hemorrhoid surgery to reduce postoperative pain

Official title: Effect of Internal Anal Sphincter Botulinum Toxin A Injection 7 Days Before Hemorrhoidectomy on Postoperative Pain: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Run by Lomonosov Moscow State University Medical Research and Educational Center · NCT07399860 · Data updated 2026-11-12

This study will see if injecting botulinum toxin A into the internal anal sphincter a week before hemorrhoidectomy reduces post-operative pain for adults with grade III–IV hemorrhoids.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment292 (estimated)
SponsorLomonosov Moscow State University Medical Research and Educational Center
Academic / other
Locations1 site (Moscow, Moscow)
StatusRecruiting
StartedFebruary 1, 2026
Main results expectedJanuary 2027
Study endsJanuary 2028
Registry record updatedMarch 10, 2026
Trial IDNCT07399860 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older with symptomatic grade III–IV hemorrhoids scheduled for open (Milligan-Morgan) or closed (Ferguson) excisional hemorrhoidectomy and without contraindications to botulinum toxin are ideal candidates.

Probably not a fit

Patients with prior anal sphincter surgery, baseline fecal incontinence, neuromuscular junction disorders, active anorectal infection or inflammatory bowel disease in the active phase, pregnancy or breastfeeding, or those who cannot safely stop anticoagulation are unlikely to receive benefit and are excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, placebo-controlled Phase 2 trial gives adult patients with symptomatic grade III–IV hemorrhoids either botulinum toxin A or saline injected into the internal anal sphincter seven days before excisional hemorrhoidectomy. Injections are performed in four quadrants using a standardized technique and both patients and surgeons are blinded to allocation. All participants undergo open or closed hemorrhoidectomy with standardized perioperative care, and postoperative pain is measured with a visual analogue scale during the first seven days. Secondary outcomes include analgesic use, complications, length of stay, transient fecal incontinence, time to first bowel movement, readmissions, and patient satisfaction within 30 days.

Why it matters

Potential benefit: If successful, preoperative botulinum toxin A could reduce postoperative pain, lower analgesic needs, and speed recovery after hemorrhoidectomy.

How similar studies have gone: Botulinum toxin A has proven effective for anal sphincter spasm and chronic anal fissure, but its preoperative use to reduce pain after hemorrhoidectomy is less well established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults ≥18 years, male and female
* Symptomatic grade III-IV hemorrhoidal disease (Goligher), refractory to conservative treatment
* Scheduled for open (Milligan-Morgan) or closed (Ferguson) hemorrhoidectomy

Exclusion Criteria:

* Known hypersensitivity to botulinum toxin A, human albumin, or local anesthetics.
* Neuromuscular junction disorders (e.g., myasthenia gravis, Lambert-Eaton syndrome).
* Use of aminoglycosides or other agents interfering with neuromuscular transmission within 14 days.
* Coagulopathy or ongoing anticoagulant therapy not suitable for perioperative interruption.
* Active anorectal infection, fissure, abscess, or inflammatory bowel disease in the active phase.
* Previous anal sphincter surgery or baseline fecal incontinence.
* Pregnancy or breastfeeding.
* ASA ≥ III or significant systemic disease compromising anesthesia or wound healing.
* Participation in another interventional clinical trial within 30 days.

Where it's running

  • Lomonosov Moscow State University Medical Research and Educational Center
    Moscow, Moscow, Russia
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.